Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

Esophageal Squamous Cell Carcinoma (ESCC), the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore (NUS) have discovered a biomarker, called adenosine deaminase acting on RNA-1 (ADAR1), which has the potential to improve the diagnosis, prognosis and treatment of this disease.

6 Jan 2014

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Esophageal Squamous Cell Carcinoma, the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore have discovered a biomarker, called adenosine deaminase acting on RNA-1, which has the potential to improve the diagnosis, prognosis and treatment of this disease.

6 Jan 2014

Researchers study health consequences of RTE proliferation that occurs in aging tissues

The genomes of organisms from humans to corn are replete with "parasitic" strands of DNA that, when not suppressed, copy themselves and spread throughout the genome, potentially affecting health. Earlier this year Brown University researchers found that these "retrotransposable elements" were increasingly able to break free of the genome's control in cultures of human cells.

27 Dec 2013

Researchers complete genomic analysis of cervical cancer in two patient populations

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer.

25 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Researchers develop possible new method for treating pancreatic cancer

A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

22 Dec 2013

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled "A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer," will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma.

19 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

Researchers discover that adult stem cells suppress cancer during dormant phase

Researchers at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered a mechanism in adult stem cells by which the cells suppress their ability to initiate cancer during their dormant phase, an understanding that could be exploited for better cancer prevention strategies.

18 Dec 2013

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.

17 Dec 2013

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma, the most common type of liver cancer.

16 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers.

13 Dec 2013

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an effective new option for breast cancer prevention for this group of women, according to initial results of a double-blind, randomized, placebo-controlled trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. The study is being simultaneously published in the The Lancet.

13 Dec 2013

HCV antiviral therapy also improves diabetes outcomes

Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.

12 Dec 2013

Low sodium levels linked to poor targeted therapy outcomes in RCC

Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate.

11 Dec 2013

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows.

11 Dec 2013

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Surefire Medical, Inc. today announced that it has completed enrollment in the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Carcinoma News and Research

Further Reading

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Researchers study health consequences of RTE proliferation that occurs in aging tissues

Researchers complete genomic analysis of cervical cancer in two patient populations

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Researchers develop possible new method for treating pancreatic cancer

Blaze Bioscience to initiate first Phase 1 clinical study of BLZ-100 in patients with skin tumors

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Researchers discover that adult stem cells suppress cancer during dormant phase

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

HCV antiviral therapy also improves diabetes outcomes

Low sodium levels linked to poor targeted therapy outcomes in RCC

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Navidea receives Fast Track designation for Lymphoseek injection

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News